Bio-Rad Laboratories (BIO) Stock Analysis & Winston Score
Bio-Rad Laboratories makes tools and equipment used by scientists and doctors to study diseases, test blood, and run experiments in labs. Its two main business segments are Life Science, which sells research instruments and chemicals to universities and drug companies, and Clinical Diagnostics, which sells blood-testing systems to hospitals and clinical labs. The company is a long-standing supplier in both fields, with products used in labs across more than 100 countries. Bio-Rad earns money by selling instruments upfront and then generating recurring revenue from the reagents and consumables those instruments require — a classic "razor and blades" model. It operates globally, with significant revenue coming from the United States, Europe, and Asia, and generates roughly $2.7 billion in annual sales. Its installed base of instruments creates some customer stickiness, but the company faces pressure from larger, better-funded competitors like Danaher and Thermo Fisher, and its low return on invested capital signals ongoing challenges in converting its scale into consistent profitability.
Winston Score: 47/100 — Average
Mixed quality — meaningful strengths and weaknesses.
- Quality: Mixed (9/30)
- Growth: Weak (4/20)
- Cash Flow: Exceptional (9/10)
- Stability: Strong (8/10)
- Valuation: Good (5/10)
- Ownership: Good (10/15)
Key Facts
Price: $304.36
Market Cap: $8.2B
Sector: Healthcare
Industry: Medical - Devices


